Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Coagulation Stories

2014-04-17 08:28:45

- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/ -- Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a...

2014-04-17 08:28:23

Donated coagulation factor supports WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 17, 2014 /PRNewswire/ -- CSL Behring announced today that the company will continue its ongoing commitment to the global coagulation disorders community with a donation of product to the World Federation of Hemophilia (WFH). The donation, provided in connection with World Hemophilia Day on April 17, supports WFH's Global Alliance for Progress (GAP) program aimed at improving the...

2014-04-16 16:26:40

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022SummaryThe competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of...

2014-04-16 08:32:37

6.9 million people have a bleeding disorder. 75 percent of them don't know it. MONTREAL, April 16, 2014 /PRNewswire/ -- Every year on April 17, World Hemophilia Day is observed around the world to increase awareness of hemophilia and other inherited bleeding disorders. In 2014, World Hemophilia Day's theme will encourage the younger generation of the global bleeding disorders community to "Speak out. Create change." "World Hemophilia Day is part of our critical effort to aid in...

2014-04-02 15:37:00

Discovery could lead to more effective therapies to prevent heart attacks Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis. Scientists at Case Western Reserve School of Medicine and University Hospitals Case Medical Center have reached a...

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-02-25 14:19:07

New approach could help doctors and surgeons diagnose blood coagulation status in near real time, significantly improving patient care Defective blood coagulation is one of the leading causes of preventable death in patients who have suffered trauma or undergone surgery. The body’s natural defense against severe blood loss is the clotting process, in which platelets, plasma proteins, and other blood components interact to form a sticky, mesh-like structure. But often things go wrong, and...

2014-02-20 08:30:34

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...

2014-02-11 12:27:14

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/h477tv/coagulation ) has announced the addition of the "Concise Analysis on the International Coagulation Self-Testing Devices, Markets, Players and Prospects" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ability of patients to self-monitor is deemed to be a critical tool in reducing the pathological effects of difficult-to-control disease...